| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress.
|
Cell Metab
|
2010
|
3.29
|
|
2
|
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease.
|
Arterioscler Thromb Vasc Biol
|
2007
|
2.47
|
|
3
|
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions.
|
Clin Chem
|
2003
|
1.74
|
|
4
|
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
1.55
|
|
5
|
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.
|
Clin Biochem
|
2004
|
1.21
|
|
6
|
Subclinical vitamin K deficiency in hemodialysis patients.
|
Am J Kidney Dis
|
2007
|
1.18
|
|
7
|
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin.
|
FASEB J
|
2006
|
1.12
|
|
8
|
Lipoprotein(a): a unique risk factor for cardiovascular disease.
|
Clin Lab Med
|
2006
|
1.12
|
|
9
|
Lipoprotein(a): more interesting than ever after 50 years.
|
Curr Opin Lipidol
|
2012
|
1.06
|
|
10
|
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).
|
J Lipid Res
|
2013
|
1.04
|
|
11
|
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
|
Clin Biochem
|
2006
|
1.00
|
|
12
|
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
|
J Biol Chem
|
2003
|
0.99
|
|
13
|
Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside.
|
Curr Opin Lipidol
|
2003
|
0.96
|
|
14
|
Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis.
|
Blood
|
2007
|
0.94
|
|
15
|
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway.
|
J Biol Chem
|
2008
|
0.91
|
|
16
|
A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor.
|
J Biol Chem
|
2002
|
0.90
|
|
17
|
Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR.
|
J Lipid Res
|
2008
|
0.89
|
|
18
|
The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells.
|
J Biol Chem
|
2003
|
0.87
|
|
19
|
A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment?
|
Semin Vasc Med
|
2002
|
0.87
|
|
20
|
Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation.
|
Biochemistry
|
2006
|
0.87
|
|
21
|
Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.86
|
|
22
|
Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly.
|
J Biol Chem
|
2003
|
0.83
|
|
23
|
Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
|
Biochemistry
|
2004
|
0.83
|
|
24
|
The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
|
Atherosclerosis
|
2009
|
0.82
|
|
25
|
Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3.
|
Biochem J
|
2009
|
0.82
|
|
26
|
Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9.
|
J Biol Chem
|
2004
|
0.82
|
|
27
|
Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10.
|
Biochemistry
|
2005
|
0.81
|
|
28
|
Update on lipoprotein(a) as a cardiovascular risk factor and mediator.
|
Curr Atheroscler Rep
|
2013
|
0.81
|
|
29
|
Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells.
|
J Biol Chem
|
2003
|
0.80
|
|
30
|
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).
|
J Lipid Res
|
2014
|
0.80
|
|
31
|
The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions.
|
Biochim Biophys Acta
|
2005
|
0.80
|
|
32
|
Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation.
|
Biochemistry
|
2004
|
0.79
|
|
33
|
Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms.
|
Int J Biochem Cell Biol
|
2013
|
0.78
|
|
34
|
Nuclear magnetic resonance (NMR) solution structure, dynamics, and binding properties of the kringle IV type 8 module of apolipoprotein(a).
|
Biochemistry
|
2007
|
0.78
|
|
35
|
Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system.
|
PLoS One
|
2013
|
0.78
|
|
36
|
Plasminogen binds to plasmin-modulated factor Xa by Ca(2+) - and C-terminal lysine-dependent and -independent interactions.
|
Thromb Haemost
|
2007
|
0.78
|
|
37
|
A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation.
|
J Biol Chem
|
2003
|
0.78
|
|
38
|
Screening for and management of elevated Lp(a).
|
Curr Cardiol Rep
|
2013
|
0.77
|
|
39
|
Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality.
|
Perit Dial Int
|
2002
|
0.77
|
|
40
|
Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone.
|
Blood Coagul Fibrinolysis
|
2013
|
0.76
|
|
41
|
Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a).
|
Mol Biol Cell
|
2012
|
0.76
|
|
42
|
Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10.
|
Biochemistry
|
2002
|
0.75
|
|
43
|
Regulation of the mouse gene encoding TAFI by TNFα: role of NFκB binding site.
|
Cytokine
|
2012
|
0.75
|
|
44
|
A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation.
|
Arch Biochem Biophys
|
2003
|
0.75
|
|
45
|
Identification of a novel apolipoprotein(a)-related protein from the European hedgehog (Erinaceus europaeus).
|
DNA Seq
|
2003
|
0.75
|
|
46
|
The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity.
|
Thromb Haemost
|
2013
|
0.75
|
|
47
|
An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
|
Arterioscler Thromb Vasc Biol
|
2005
|
0.75
|
|
48
|
Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter.
|
Br J Haematol
|
2007
|
0.75
|
|
49
|
Activated protein C resistance and low molecular weight lipoprotein (a): dual pathogens for atherothrombosis?
|
Thromb Res
|
2005
|
0.75
|